---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Prevalence"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Prevalence. Topics: Bladder cancer prevalence in the United States; Prevalent population eligible for treatment of BCG-unresponsive high-risk NMIBC, ICER estimate; Eligible population per 1 million health plan members, budget impact model estimate; Limits of classifying BCG-unresponsive disease in real-world data. 4 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description/prevalence"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Prevalence

<a id="heading-2.2.1.2.2"></a>

## 2.2.1.2.2 Prevalence of BCG-unresponsive high-risk non-muscle-invasive bladder cancer

<a id="topic-2.2.1.2.2-1"></a>

### Bladder cancer prevalence in the United States

> “In 2023, there were an estimated 763,031 people living with bladder cancer in the United States.”

Source: [SEER Cancer Stat Facts Bladder Cancer (2026)](https://seer.cancer.gov/statfacts/html/urinb.html)

> “Bladder cancer (BC) is a malignancy commonly affecting elderly people, with a prevalence of 744,039 individuals in the United States (US) in 2022”

Source: [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037)

<a id="topic-2.2.1.2.2-2"></a>

### Prevalent population eligible for treatment of BCG-unresponsive high-risk NMIBC, ICER estimate

> “The National Cancer Institute’s Surveillance, Epidemiology and End Results Program (SEER) estimates that prevalence of bladder cancer was 712,614 people in the US in 2017”
> “Applying these proportions to the estimated prevalent NMIBC population (712,614), we arrived at an estimate of 70,135 individuals as the eligible population for these treatments, with 73% (51,180) being Ta and T1 patients and 27% (18,956) being CIS patients.”

Source: [ICER Bladder Cancer Final Evidence Report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_Bladder_Cancer_Final_Report_07292022.pdf)

<a id="topic-2.2.1.2.2-3"></a>

### Eligible population per 1 million health plan members, budget impact model estimate

> “In a hypothetical health plan with one million lives, the number of adults with high-risk, BCG-unresponsive NMIBC with CIS ± Ta/T1 who were eligible for nadofaragene firadenovec was estimated to be 5.5 in Year 1, 4.9 in Year 2, and 4.5 in Year 3”
> “when considering the broader population eligible for nadofaragene firadenovec to the pooled population of CIS ± Ta/T1 plus Ta/T1 only, the size of the target population was estimated to be 33.2 patients in Year 1, 29.7 in Year 2, and 27.5 in Year 3.”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-2.2.1.2.2-4"></a>

### Limits of classifying BCG-unresponsive disease in real-world data

> “As a result, a substantial proportion of patients cannot be classified under existing criteria because the exposure-based and time-dependent conditions required by regulatory definitions are not met in routine practice.”
> “Maintenance BCG is infrequently delivered, surveillance intervals vary widely, early radical cystectomy is limited by system-level and institutional factors, and key tumour-level variables required for classification are often missing in large-scale datasets.”

Source: [Pinton et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13464600/)

> “Adequate BCG maintenance therapy was uncommon; only 24.9% (4951 of 19 889) of patients across all risk groups received maintenance therapy.”

Source: [Giatsoglou et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13087816/)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
